These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17373723)

  • 41. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
    Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
    Bibbiani F; Costantini LC; Patel R; Chase TN
    Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
    Pugsley TA; Lippmann W
    Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice.
    Gunzler SA; Shakil S; Carlson NE; Nutt JG; Meshul CK
    Neurosci Lett; 2007 Nov; 428(2-3):64-7. PubMed ID: 17964074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Hansard MJ; Jackson MJ; Smith LA; Rose S; Jenner P
    Behav Pharmacol; 2011 Jun; 22(3):269-74. PubMed ID: 21522056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
    Fredriksson A; Palomo T; Archer T
    J Neural Transm (Vienna); 1999; 106(9-10):889-909. PubMed ID: 10599871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
    Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
    Yang X; Yuan W; Ren T; Song L; Wu N; Liu Z
    Neuroreport; 2010 Aug; 21(12):837-40. PubMed ID: 20631586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Luthra PM; Barodia SK; Raghubir R
    J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
    Gonce M; Barbeau A
    Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
    van Vliet SA; Vanwersch RA; Jongsma MJ; Olivier B; Philippens IH
    Eur Neuropsychopharmacol; 2008 May; 18(5):383-9. PubMed ID: 18222654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
    Xu DL; Yu WC; Pan GB; Chen SD
    Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
    Ardashov OV; Pavlova AV; Il'ina IV; Morozova EA; Korchagina DV; Karpova EV; Volcho KP; Tolstikova TG; Salakhutdinov NF
    J Med Chem; 2011 Jun; 54(11):3866-74. PubMed ID: 21534547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
    Fox SH; Visanji NP; Johnston TH; Gomez-Ramirez J; Voon V; Brotchie JM
    Arch Neurol; 2006 Sep; 63(9):1343-4. PubMed ID: 16966523
    [No Abstract]   [Full Text] [Related]  

  • 58. [Study of an MPTP-induced parkinsonian animal model in the rhesus monkey and the mechanism of the action of MPTP].
    Chen S
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Feb; 23(1):23-6, 62. PubMed ID: 1971785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
    Quik M; Cox H; Parameswaran N; O'Leary K; Langston JW; Di Monte D
    Ann Neurol; 2007 Dec; 62(6):588-96. PubMed ID: 17960553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.
    Papa SM; Auberson YP; Greenamyre JT
    Ann Neurol; 2004 Nov; 56(5):723-7. PubMed ID: 15470750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.